Issues
-
Cover Image
Cover Image
Disorganized tumor vasculature leads to poor perfusion and hypoxia, both contributing to cytoxic treatment failure. The authors show that treatment of tumors with drugs that target EGFR-ras-PI3K-AKT signaling (STIs) improves vascular function. The image from a tumor treated with Nefinavir shows in blue the Hoechst dye indicating perfusion seen between the GFP labelled tumor cells and the red stained vessels. Quantitation of such images revealed that STI treatment improved blood flow, enhanced vascular maturation and eliminated hypoxia. This could create a new paradigm for the use of STIs to condition tumors for therapy with drugs or radiation. For details, see the article by Qayum and colleagues on page 6347 of this issue. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Reviews
Meeting Report
Priority Reports
Cell, Tumor, and Stem Cell Biology
Clinical Research
Endocrinology
Androgen Receptor Inhibits Estrogen Receptor-α Activity and Is Prognostic in Breast Cancer
Epidemiology
Experimental Therapeutics, Molecular Targets, and Chemical Biology
Comparison of Human and Rat Uterine Leiomyomata: Identification of a Dysregulated Mammalian Target of Rapamycin Pathway
The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity
Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
Immunology
Intratumoral Induction of CD103 Triggers Tumor-Specific CTL Function and CCR5-Dependent T-Cell Retention
Immunity to Murine Prostatic Tumors: Continuous Provision of T-Cell Help Prevents CD8 T-Cell Tolerance and Activates Tumor-Infiltrating Dendritic Cells
Inhibition of Superoxide Generation upon T-Cell Receptor Engagement Rescues Mart-127-35–Reactive T Cells from Activation-Induced Cell Death
Molecular Biology, Pathobiology, and Genetics
3-Phosphoinositide–Dependent Kinase 1 Potentiates Upstream Lesions on the Phosphatidylinositol 3-Kinase Pathway in Breast Carcinoma
Differentiation of Lung Adenocarcinoma, Pleural Mesothelioma, and Nonmalignant Pulmonary Tissues Using DNA Methylation Profiles
Tumor Microenvironment
Letters to the Editor
Corrections
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.